TransMedics Group (NASDAQ:TMDX) Stock Price Up 6.6% – Time to Buy?

TransMedics Group, Inc. (NASDAQ:TMDX)’s stock price was up 6.6% on Tuesday . The company traded as high as $64.80 and last traded at $65.10. Approximately 473,159 shares changed hands during trading, a decline of 84% from the average daily volume of 2,965,165 shares. The stock had previously closed at $61.07.

Analysts Set New Price Targets

Several research firms have recently issued reports on TMDX. TD Cowen lowered their price target on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. Oppenheimer reissued an “outperform” rating and set a $125.00 target price on shares of TransMedics Group in a report on Tuesday, December 3rd. JPMorgan Chase & Co. restated a “neutral” rating and set a $75.00 target price (down previously from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Canaccord Genuity Group reduced their price target on TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research report on Wednesday, November 20th. Finally, Robert W. Baird decreased their price objective on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $122.70.

TransMedics Group Price Performance

The business has a 50 day simple moving average of $68.25 and a two-hundred day simple moving average of $113.99. The firm has a market capitalization of $2.25 billion, a P/E ratio of 71.31 and a beta of 2.12. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The company had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. TransMedics Group’s quarterly revenue was up 63.7% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.12) EPS. On average, sell-side analysts expect that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insider Buying and Selling

In other TransMedics Group news, Director Edward M. Basile sold 6,750 shares of the stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total transaction of $563,962.50. Following the transaction, the director now directly owns 732 shares in the company, valued at $61,158.60. This trade represents a 90.22 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Tamer I. Khayal sold 1,084 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the sale, the insider now owns 20,843 shares of the company’s stock, valued at approximately $1,800,835.20. The trade was a 4.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Amalgamated Bank boosted its stake in shares of TransMedics Group by 6.7% during the 2nd quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock valued at $168,000 after purchasing an additional 70 shares in the last quarter. Harbour Capital Advisors LLC lifted its holdings in TransMedics Group by 1.7% in the third quarter. Harbour Capital Advisors LLC now owns 4,841 shares of the company’s stock worth $760,000 after buying an additional 81 shares during the period. Venturi Wealth Management LLC boosted its position in TransMedics Group by 33.7% during the 3rd quarter. Venturi Wealth Management LLC now owns 869 shares of the company’s stock valued at $136,000 after acquiring an additional 219 shares in the last quarter. National Bank of Canada FI grew its holdings in shares of TransMedics Group by 174.7% during the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after acquiring an additional 262 shares during the period. Finally, Quarry LP raised its position in shares of TransMedics Group by 557.1% in the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after acquiring an additional 312 shares in the last quarter. 99.67% of the stock is owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.